LB-B021 - R. Wenham - Open label, multicenter, phase 2 study of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), alone and in combination with lenvatinib in platinum-resistant ovarian cancer (PROC)